Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 4/20 | 0.31 |
| ▸ | DRD2 | P14416 | 4/20 | 0.31 |
| ▸ | HTR2A | P28223 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9538244 | 0.75 | PLK1 (0.43) | PLK1CSNK2A1PLK3HIF1AHTR1A | |
| SCHEMBL9536915 | 0.70 | HTR1A (0.30) | HTR1ADRD2HTR2A | |
| SCHEMBL9216439 | 0.69 | PLK1 (0.40) | PLK1CSNK2A1PLK3HIF1A | |
| SCHEMBL9534430 | 0.67 | PLK1 (0.56) | PLK1CSNK2A1PLK3HIF1AHTR1A | |
| SCHEMBL22048856 | 0.65 | HTR2A (0.45) | PLK1CSNK2A1PLK3HIF1AHTR1A | |
| SCHEMBL22048623 | 0.63 | PLK1 (0.50) | PLK1CSNK2A1PLK3HIF1AHTR1A | |
| SCHEMBL9218236 | 0.61 | PLK1 (0.47) | PLK1CSNK2A1PLK3HIF1AHTR1A | |
| SCHEMBL22980483 | 0.60 | PLK1 (0.79) | PLK1CSNK2A1PLK3HIF1AHTR1A | |
| SCHEMBL26984389 | 0.60 | CSNK2A1 (0.56) | PLK1CSNK2A1PLK3HIF1AHTR2A | |
| SCHEMBL9535703 | 0.60 | PLK1 (0.61) | PLK1CSNK2A1PLK3HIF1AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0276835-B1 | PYRAZOLOTHIOPYRANOPYRAZOLES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-03-17 | — | — | EP | claimed |
| US-20100145056-A1 | ACETYL 2-HYDROXY-1,3-DIAMINOALKANES | JOHN VARGHESE | 2010-06-10 | — | — | US | disclosed |
| US-20100145056-A1 | ACETYL 2-HYDROXY-1,3-DIAMINOALKANES | JOHN VARGHESE | 2010-06-10 | — | — | US | disclosed |
| US-7645780-B2 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645780-B2 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7544717-B2 | 2-amino- and 2-thio- substituted 1,3-diaminopropanes | ELAN PHARMACEUTICALS, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544717-B2 | 2-amino- and 2-thio- substituted 1,3-diaminopropanes | ELAN PHARMACEUTICALS, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20070293483-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293483-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-7244725-B2 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244725-B2 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| EP-0532693-A1 | 1,4-DIAMINO-2,3-DIHYDROXYBUTANES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-03-24 | — | — | EP | disclosed |
| EP-0276835-B1 | PYRAZOLOTHIOPYRANOPYRAZOLES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-03-17 | — | — | EP | disclosed |
| EP-0276835-A1 | Pyrazolothiopyranopyrazoles | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-08-03 | — | — | EP | disclosed |
| US-4734431-A | Thiopyranodipyrazoles and their use as bronchodilators | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145056-A1 | ACETYL 2-HYDROXY-1,3-DIAMINOALKANES | BACE1, BACE2, APP | PLK1 4300/4885CSNK2A1 820/4885PLK3 4174/4885 |
| US-20070293483-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | BACE1, BACE2, APP | PLK1 4300/4885CSNK2A1 820/4885PLK3 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.